Pharma & Biotech — November 2, 2026 Weekly
Pharma & Biotech news & updates — every claim linked to a primary source.
Key Findings
Executive Summary (4)
- •The week's defining narrative is the simultaneous acceleration of breakthrough oncology programs and the emergence of serious safety headwinds: the Moderna-Merck cancer vaccine moved from Phase 3 validation to FDA submission planning for 2027, while the autoimmune CAR-T field suffered a second company shutdown after patient deaths — a juxtaposition that illustrates how rapidly the frontier of medicine can shift from triumph to crisis within the same modality class.
- •The GLP-1 competitive landscape underwent a structural shift as Lilly's retatrutide beat Ozempic head-to-head in diabetes, signaling that the next generation of triple-receptor agonists may displace current market leaders — a development that, combined with Lilly's third consecutive quarter of revenue beats, positions the company as the dominant force in the most commercially significant drug class of the decade.
- •Regulatory authorities diverged sharply in their approaches to evidence standards this week: the MHRA approved Casgevy's paediatric gene-editing extension and maintained rigorous approval standards, while HHS overrode FDA career scientists to allow compounding of six experimental peptides without established safety or efficacy data — a pattern that signals growing political pressure on the FDA's evidence-based framework with implications for regulatory credibility.
- •The COINS rule debate matured from a binary question of whether to restrict China biotech investment to a nuanced argument about the licensing exemption's scope — a shift that suggests the rule will be implemented but its practical impact on deal-making will depend heavily on how Treasury defines the boundaries of permissible licensing transactions, keeping the US-China biotech relationship in a state of structured uncertainty.
Key Points (15)
- 1.Moderna CEO Stéphane Bancel told STAT News on 2026-10-26 that Moderna and Merck are racing to submit intismeran for FDA approval, expected in 2027, and are preparing to test it in other cancers beyond melanoma [2a].
- 2.Eli Lilly announced on 2026-10-28 that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk's Ozempic in a large diabetes study [2b].
- 3.STAT News reported on 2026-10-27 that Artiva is shutting down after two patient deaths in autoimmune cell therapy trials, escalating the CAR-T safety crisis beyond the BMS patient death reported last week [2].
- 4.Merck announced on 2026-10-26 that sacituzumab tirumotecan reduced the risk of death by 32% and risk of disease progression or death by 41% compared to chemotherapy in advanced endometrial cancer [3].
- 5.Merck also announced on 2026-10-26 that KEYTRUDA as monotherapy reduced the risk of disease progression or death by 43% for certain endometrial cancer patients with dMMR tumors [3].
- 6.Pfizer announced on 2026-10-26 that TALZENNA plus XTANDI received FDA approval for an earlier metastatic prostate cancer treatment setting, and on 2026-10-27 that ELREXFIO met its primary endpoint in Phase 3 multiple myeloma [7].
- 7.J&J announced on 2026-10-25 that RYBREVANT FASPRO demonstrated a 77% overall response rate in first-line advanced head and neck cancer [10].
- 8.STAT News reported on 2026-10-26 that Roche's KRAS drug divarasib secured a lung cancer win over Amgen and Bristol Myers Squibb [2].
- 9.The MHRA approved on 2026-10-30 an extension of Casgevy (exagamglogene autotemcel) to treat children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia [13].
- 10.HHS issued a policy on 2026-10-28 allowing compounding of six experimental peptides including BPC-157 and TB-500 despite objections from FDA career scientists [15].
- 11.STAT News reported on 2026-10-29 that the biopharma industry is divided over the COINS rule's impact, with a licensing exemption confirmed by a Treasury official at the center of disagreements [14].
- 12.STAT News reported on 2026-10-27 that the FDA offered new details on a quicker approval pathway for personalized gene therapies [2].
- 13.The EMA's PRAC started a review of depression and anxiety medicine Deanxit and identified a safety signal related to human normal immunoglobulin medicines, published 2026-10-30 [4].
- 14.Japan's PMDA suspended its medical device web application platform (DWAP) on 2026-10-29 following unauthorized access detected between October 23-26, with no confirmed restart date [5].
- 15.Endpoints News reported on 2026-10-29 that Eli Lilly beat revenue forecasts, lifting its full-year outlook for the third straight quarter [8].
Market Trends
mRNA Cancer Vaccine Platform Moves Toward FDA Submission After Phase 3 Confirmation
Building on last week's Phase 3 data confirmation at ESMO, Moderna CEO Stéphane Bancel told STAT News on 2026-10-26 that Moderna and Merck are racing to submit intismeran for FDA approval, which he expects in 2027, and are preparing to test it aggressively in other cancers beyond melanoma [2a]. The transition from data readout to active FDA submission planning signals the mRNA cancer vaccine platform is entering a commercialisation phase, with competitive implications for every oncology company …
GLP-1 Competition Intensifies as Lilly's Triple-G Drug Outperforms Ozempic in Head-to-Head
Eli Lilly announced on 2026-10-28 that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk's Ozempic in a large diabetes study, according to STAT News [2b]. Endpoints News corroborated the head-to-head result on 2026-10-28 [8]. This direct competitive displacement of the market-leading GLP-1 signals that the obesity and diabetes drug market is entering a next-generation phase where triple-receptor agonists may structurally outcompe…
US-China Biotech Decoupling Debate Deepens as Industry Splits Over COINS Rule Impact
Following the Treasury's COINS proposal reported last week, STAT News reported on 2026-10-29 that the biopharma industry is at odds over the impact of the new China rule, with debate centering on a licensing exemption that a Treasury official confirmed [14]. The core disagreement — whether to play offense by boosting domestic R&D or defense by restricting Chinese access — reflects a structural industry divide that will shape deal-making strategy for years. Endpoints News also noted on 2026-10-25…
Autoimmune CAR-T Safety Crisis Deepens as Artiva Shuts Down After Two Patient Deaths
STAT News reported on 2026-10-27 that after two deaths in autoimmune cell therapy trials, Artiva is shutting down [2]. This follows the Bristol Myers Squibb CAR-T patient death reported last week. The pattern of multiple trial deaths across different companies in the same week signals a systemic safety challenge for the autoimmune CAR-T modality, not an isolated event, and is likely to trigger heightened regulatory scrutiny and investor caution across the field.
Big Pharma Cost-Cutting Wave Accelerates as AstraZeneca and GSK Announce Savings Pushes
Endpoints News reported on 2026-10-30 that AstraZeneca announced a reorganisation that could mean R&D cuts and trials shifted to emerging markets, following GSK with a $1.5 billion annual savings push [8]. AstraZeneca's stated goal of $80 billion in revenue by 2030 is driving cost discipline even as late-stage trial failures mount. This parallel cost-cutting by two of Europe's largest pharma companies reflects broader pressure on the sector from pricing constraints, geopolitical uncertainty, and…
Competitor Trends
Merck Advances Dual Oncology Fronts: ADC Cuts Death Risk by 32% and Q3 Results Highlight Pipeline
Merck announced on 2026-10-26 that sacituzumab tirumotecan (Sac-TMT) reduced the risk of death by 32% and the risk of disease progression or death by 41% compared to chemotherapy in certain patients with advanced or recurrent endometrial cancer [3] (company announcement — may reflect promotional framing). On the same date, KEYTRUDA as monotherapy reduced the risk of disease progression or death by 43% for certain endometrial cancer patients with dMMR tumors [3]. Merck also announced Q3 2026 fina…
Pfizer Secures FDA Approval for ELREXFIO in Multiple Myeloma and TALZENNA in Prostate Cancer
Pfizer announced on 2026-10-27 that ELREXFIO outperformed standard regimens and met its primary endpoint in a Phase 3 study in relapsed or refractory multiple myeloma [7] (company announcement — may reflect promotional framing). On 2026-10-26, Pfizer announced that TALZENNA plus XTANDI received FDA approval for an earlier metastatic prostate cancer treatment setting [7] (company announcement — may reflect promotional framing). These back-to-back approvals and positive Phase 3 data across two dis…
Johnson & Johnson Expands Oncology Data Package with RYBREVANT FASPRO Head and Neck Results
J&J announced on 2026-10-25 that RYBREVANT FASPRO demonstrated a 77% overall response rate in first-line treatment of patients with advanced head and neck cancer, with 65% of responses ongoing at clinical cutoff [10] (company announcement — may reflect promotional framing). This builds on J&J's ESMO data package from the prior week and extends the RYBREVANT franchise from lung cancer into head and neck cancer, where EGFR and MET are key drivers of tumor growth and resistance in 80 to 90 percent …
Roche Wins Lung Cancer Battle with KRAS Drug Divarasib Over Amgen and BMS
STAT News reported on 2026-10-26 that Roche's KRAS drug divarasib secured a lung cancer win over Amgen and Bristol Myers Squibb [2]. Endpoints News corroborated the competitive victory on 2026-10-25, describing Roche taking a victory lap with its lung cancer pill's win over Amgen and BMS [8]. This outcome in the competitive KRAS inhibitor space — where Amgen's sotorasib was the first approved — positions Roche as a leading contender in one of oncology's most actively contested target classes.
Lilly Beats Revenue Forecasts for Third Straight Quarter as GLP-1 Dominance Grows
Endpoints News reported on 2026-10-29 that Eli Lilly beat revenue forecasts, lifting its full-year outlook for the third straight quarter [8]. This financial outperformance, combined with the retatrutide head-to-head win over Ozempic reported on 2026-10-28 [2b], positions Lilly as the dominant force in the GLP-1 market with both current commercial momentum and a next-generation pipeline asset that may further extend its lead over Novo Nordisk.
Regulatory Trends
MHRA Approves Gene-Editing Treatment for Children and Rare Disease Drug in Active Approval Week
The MHRA approved on 2026-10-30 an extension of Casgevy (exagamglogene autotemcel) authorisation to treat children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, and also approved triheptanoin (Dojolvi) for adults and children with rare inherited disorders [13]. The MHRA also updated its clinical trials hub on 2026-10-29, adding a blog on six months since implementation of the UK's new clinical trials regulations [16]. The MHRA's continued high-volume…
FDA Outlines Personalized Gene Therapy Approval Pathway and Publishes New Drug Delivery Guidance
STAT News reported on 2026-10-27 that the FDA offered new details on a quicker approval pathway for personalized gene therapies [2]. Endpoints News corroborated on 2026-10-29 that the FDA charted a path for approval of individualized gene editing therapies, outlining steps drugmakers can take to seek regulatory approval for gene editing medicines tailored to fix a single person's disease-causing mutation [8]. The FDA also published guidance on essential drug delivery performance characteristics …
HHS Overrides FDA Scientists to Allow Compounding of Six Experimental Peptides
STAT News reported on 2026-10-29 that HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including BPC-157 and TB-500, without fear of federal enforcement, despite objections from FDA career scientists who say there is scant evidence the substances are safe or effective [15]. Endpoints News corroborated on 2026-10-29 that HHS cited 'safety' and 'freedom' in allowing compounding of certain wellness peptides [8]. This represents a sig…
EMA PRAC Initiates Safety Review of Depression Medicine Deanxit and Immunoglobulin Signal
The EMA's Pharmacovigilance Risk Assessment Committee published meeting highlights on 2026-10-30 showing that PRAC started a review of depression and anxiety medicine Deanxit and identified a safety signal related to human normal immunoglobulin medicines [4]. These new safety reviews add to the EMA's ongoing pharmacovigilance workload and signal active post-market surveillance activity for both a widely used antidepressant combination and a broad class of immunoglobulin products.
PMDA Cybersecurity Incident Forces Suspension of Medical Device Web Application Platform
Japan's PMDA announced on 2026-10-29 that its medical device web application platform (DWAP) was suspended following unauthorized access detected between October 23-26, 2026, due to system vulnerabilities [5]. PMDA stated that while traces of unauthorized access were confirmed, no information leakage, data falsification, or destruction was identified. The suspension of DWAP — with no confirmed restart date — disrupts the digital submission pathway for medical device applications in Japan, requir…
Sources Activity
Since last week
Moderna-Merck Cancer Vaccine FDA Submission Targeted for 2027
Following last week's Phase 3 data confirmation at ESMO, Moderna CEO Stéphane Bancel told STAT News on 2026-10-26 that the companies are racing to submit intismeran for FDA approval, expected in 2027, and are preparing to test it in other cancers [2a]. This updates the prior period's Phase 3 data readout milestone — the program has now moved from clinical validation to active regulatory submission planning.
Autoimmune CAR-T Safety Crisis: Artiva Shuts Down After Second Death
STAT News reported on 2026-10-27 that Artiva is shutting down after two patient deaths in autoimmune cell therapy trials [2]. This escalates the prior period's BMS CAR-T patient death from an isolated safety event to a pattern across multiple companies, deepening the safety crisis for the autoimmune CAR-T modality and likely triggering heightened regulatory scrutiny.
COINS Rule Industry Debate: Licensing Exemption at Center of Disagreement
STAT News reported on 2026-10-29 that the biopharma industry is divided over the impact of the Treasury's COINS rule, with a licensing exemption confirmed by a Treasury official now at the heart of disagreements [14]. This updates the prior period's initial COINS proposal item — the debate has shifted from whether restrictions are needed to what the practical impact of the licensing carve-out will be.
MHRA Approves Casgevy Gene-Editing Extension for Paediatric Blood Disorders
The MHRA approved on 2026-10-30 an extension of Casgevy (exagamglogene autotemcel) authorisation to treat children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, and also approved triheptanoin (Dojolvi) for rare inherited metabolic disorders [13]. This is the first paediatric extension of the gene-editing therapy's UK authorisation and represents a significant milestone for gene-editing in rare disease.
HHS Overrides FDA Scientists on Peptide Compounding Policy
HHS issued a policy on 2026-10-28 allowing licensed pharmacies and physicians to temporarily compound six experimental peptides including BPC-157 and TB-500 without federal enforcement, overriding FDA career scientists who cited lack of safety and efficacy evidence [15]. This represents a new pattern of political override of FDA scientific judgment with implications for regulatory integrity.
Watchlist — Upcoming Deadlines
20th Global Forum for Qualified Persons for Pharmacovigilance (QPPV) — DIA/EFPIA partner event
Source: EFPIASignal over noise: what will make AI stick in pharma R&D — Johnson & Johnson event listed on EFPIA
Source: EFPIAEMA Clinical Trial Applications Advice Pilot becomes permanent — technical and regulatory support for preparing clinical trial applications continues from January 2027
Source: EMA NewsStrategic Insights (9)
- 1.Moderna CEO Bancel's 2027 FDA submission target for intismeran [2a] means the mRNA cancer vaccine competitive window is now measured in months, not years — companies without a comparable program face a narrowing opportunity to enter the adjuvant melanoma market before Merck-Moderna establishes a dominant position.
- 2.The Artiva shutdown after two CAR-T deaths [2] combined with the prior week's BMS death creates a pattern that regulators cannot ignore — the FDA is likely to impose heightened safety monitoring requirements across all autoimmune CAR-T trials, potentially slowing the entire field and shifting competitive advantage toward bispecific antibodies with more established safety profiles.
- 3.Lilly's retatrutide head-to-head win over Ozempic [2b] creates a strategic dilemma for Novo Nordisk: its current market leadership rests on a drug that has now been clinically outperformed, requiring accelerated development of its own next-generation pipeline to defend its position.
- 4.The MHRA's approval of Casgevy for children aged five and over [13] establishes the UK as the first jurisdiction to extend gene-editing therapy authorisation to this paediatric population, reinforcing the MHRA's role as a first-mover regulator for novel modalities and creating a reference point for EMA and FDA paediatric extension applications.
- 5.HHS overriding FDA scientists on peptide compounding [15] sets a precedent that political considerations can supersede career scientific judgment at the FDA — a development that could undermine the agency's credibility with international regulatory partners and create uncertainty for companies relying on evidence-based approval pathways.
- 6.The COINS licensing exemption debate [14] suggests that Western pharma's China drug sourcing strategy will shift further toward pure licensing arrangements and away from equity co-development — a structural change that benefits Chinese biotechs who retain equity upside while limiting US investors' participation in China's drug discovery growth.
- 7.Merck's simultaneous advancement of both KEYTRUDA and sacituzumab tirumotecan in endometrial cancer [3] illustrates a strategy of owning multiple treatment lines in the same indication — a competitive moat that makes it difficult for single-asset competitors to displace Merck even if they win in one line of therapy.
- 8.The PMDA cybersecurity incident and DWAP suspension [5] highlights the vulnerability of digital regulatory submission infrastructure to cyberattacks — a risk that is likely to prompt other regulatory agencies to audit their own submission platforms and potentially accelerate investment in cybersecurity for regulatory IT systems globally.
- 9.IFPMA and EFPIA's joint statements at the 76th WHO Regional Committee for Europe on AI in health and non-communicable disease strategy [1] signal that the industry is actively shaping the WHO European Region's AI health roadmap for 2026-2033, positioning pharma as a partner rather than a subject of AI regulation — a strategic posture that could influence how AI-generated evidence is treated in future regulatory submissions.
Trust Summary
16 sources cited this weekDetected across 15 monitored URLs you selected — one URL can surface multiple articles.
Each source is weighted by its trust level. Single-source claims are flagged as unverified during AI synthesis.
Sources
IFPMA delivered multiple statements at the 76th WHO Regional Committee for Europe in Copenhagen (2026-10-27 to 2026-10-29) covering AI in health roadmap 2026-2033, NCD strategy, global health architecture reform, and issued a statement at close of CBD COP17 on biodiversity commitments (2026-10-31).
STAT News reporting covering Moderna CEO's FDA submission plans for intismeran (2026-10-26), Artiva shutdown after two CAR-T deaths (2026-10-27), Lilly retatrutide head-to-head win over Ozempic (2026-10-28), HHS peptide compounding policy overriding FDA scientists (2026-10-29), COINS rule industry debate (2026-10-29), FDA personalized gene therapy pathway details (2026-10-27), Roche divarasib lung cancer win (2026-10-26), and Merck ADC endometrial cancer data (2026-10-26).
Merck press releases covering sacituzumab tirumotecan 32% death risk reduction in endometrial cancer (2026-10-26), KEYTRUDA 43% disease progression/death risk reduction in dMMR endometrial cancer (2026-10-26), and Q3 2026 financial results highlighting pipeline milestones (2026-10-29).
EMA news covering PRAC October 26-29 meeting highlights showing initiation of Deanxit safety review and human normal immunoglobulin safety signal (2026-10-30), and EMA office closure notice for All Souls' Day (2026-10-29).
PMDA updates covering cybersecurity incident and DWAP medical device web application platform suspension following unauthorized access detected October 23-26 (2026-10-29), GLP-1 receptor agonist appropriate use guidance (2026-10-30), 20th Japanese Pharmacopoeia draft preparation guidelines public comment (2026-10-30), and multiple safety notices including rizatriptan nitrosamine detection (2026-10-28).
EFPIA content stable with ongoing advocacy on EU competitiveness, access to medicines, and upcoming events including 20th Global Forum for Qualified Persons for Pharmacovigilance on 2026-11-17 and AI in pharma R&D event on 2026-12-03.
Pfizer press releases covering TALZENNA plus XTANDI FDA approval for earlier metastatic prostate cancer setting (2026-10-26) and ELREXFIO Phase 3 primary endpoint met in relapsed/refractory multiple myeloma (2026-10-27).
Endpoints News reporting on Lilly triple-G retatrutide beating Ozempic in diabetes (2026-10-28), Artiva winding down after two autoimmune CAR-T deaths (2026-10-27), AstraZeneca $1.5B savings push and R&D reorganisation (2026-10-30), Lilly Q3 revenue beats for third straight quarter (2026-10-29), COINS rule narrowing China biotech deal-making paths (2026-10-28), and HHS peptide compounding policy (2026-10-29).
Nature Biotechnology publishing new research articles on engineered compact Cas12m variant for multiplexed gene activation in vivo (2026-10-28) and mRNA-lipid nanoparticle vaccine against H5N1 influenza protecting dairy cows (2026-10-28), alongside ongoing coverage of AI in peer review and gene editing advances.
J&J press releases covering RYBREVANT FASPRO 77% overall response rate in first-line advanced head and neck cancer (2026-10-25) and Impella heart pump data at TCT 2026 (2026-10-29).
DIA Global updated content on China's path to innovation using RWE and value, and Singapore's rise as a regulatory leader, alongside ongoing DIA-MHRA Global Summit announcement.
FDA published guidance on essential drug delivery performance characteristics for devices intended to deliver drugs and biological products (2026-10-29) and E14/S7B QT/QTc interval prolongation guidance update (2026-10-30).
MHRA press releases covering approval of Casgevy gene-editing treatment extension for children aged five and over with sickle-cell disease and β-thalassemia (2026-10-30), approval of triheptanoin (Dojolvi) for rare inherited disorders (2026-10-30), new MHRA research on needle-free Strep A vaccine (2026-10-27), and multiple Class 2 medicines recalls and field safety notices.
STAT News detailed reporting on biopharma industry disagreement over the COINS rule's impact, with the licensing exemption confirmed by a Treasury official at the center of debate about whether restrictions will meaningfully affect deal-making.
STAT News reporting on HHS policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides including BPC-157 and TB-500, despite FDA career scientists' objections citing lack of safety and efficacy evidence.
MHRA clinical trials hub updated on 2026-10-29 with a blog on six months since implementation of the UK's new clinical trials regulations, which took full effect on 28 April 2026.
Get Pharma & Biotech monitored every week
This report was built from primary sources only — no aggregators. Pick your themes and sources, and OriginBrief delivers a cited report like this every week. Start your 7-day free trial — plans from $33/mo.
Start your 7-day free trial